A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled, and Active-Referenced Study Evaluating the Efficacy and Safety of Three Fixed Dose Regimens of Lu AA34893 in the Treatment of Major Depressive Disorder.
Phase of Trial: Phase II
Latest Information Update: 22 Dec 2012
At a glance
- Drugs LU AA34893 (Primary) ; Venlafaxine (Primary)
- Indications Major depressive disorder
- Focus Pharmacogenomic; Therapeutic Use
- 19 May 2012 Company (Pfizer) added to he associations filed as reported by European Clinical Trials Database record.
- 28 Apr 2012 Additional trial location added as reported by European Clinical Trials Database.
- 12 Apr 2012 Additional trial locations added as reported by European Clinical Trials Database.